Evaluating the Ups and Downs of Aldeyra Therapeutics Inc’s (ALDX) Stock

In the past week, ALDX stock has gone up by 23.26%, with a monthly decline of -15.88% and a quarterly surge of 1.14%. The volatility ratio for the week is 8.45%, and the volatility levels for the last 30 days are 6.79% for Aldeyra Therapeutics Inc The simple moving average for the past 20 days is 11.12% for ALDX’s stock, with a -26.79% simple moving average for the past 200 days.

Is It Worth Investing in Aldeyra Therapeutics Inc (NASDAQ: ALDX) Right Now?

Additionally, the 36-month beta value for ALDX is 1.52. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for ALDX is 56.55M and currently, short sellers hold a 3.23% ratio of that float. The average trading volume of ALDX on April 03, 2024 was 497.84K shares.

ALDX) stock’s latest price update

Aldeyra Therapeutics Inc (NASDAQ: ALDX)’s stock price has gone rise by 8.56 in comparison to its previous close of 3.27, however, the company has experienced a 23.26% increase in its stock price over the last five trading days. Seeking Alpha reported 2024-03-24 that Lead asset, reproxalap, has clear path to regulatory approval in Dry Eye Disease. Option deal for commercial license with AbbVie signed – $400M in milestones, 60/40 profit shares of US market and tiered double-digit royalties for ex-US. $142M in cash at 12/31/23, burning $40M per year – plenty of cash to achieve monetization of reproxalap.

Analysts’ Opinion of ALDX

H.C. Wainwright, on the other hand, stated in their research note that they expect to see ALDX reach a price target of $15. The rating they have provided for ALDX stocks is “Buy” according to the report published on April 27th, 2022.

H.C. Wainwright gave a rating of “Buy” to ALDX, setting the target price at $26 in the report published on February 08th of the previous year.

ALDX Trading at 7.91% from the 50-Day Moving Average

After a stumble in the market that brought ALDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.34% of loss for the given period.

Volatility was left at 6.79%, however, over the last 30 days, the volatility rate increased by 8.45%, as shares sank -12.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.26% upper at present.

During the last 5 trading sessions, ALDX rose by +23.26%, which changed the moving average for the period of 200-days by -66.04% in comparison to the 20-day moving average, which settled at $3.17. In addition, Aldeyra Therapeutics Inc saw 1.14% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ALDX starting from Brady Todd C, who sale 85,324 shares at the price of $3.05 back on Mar 12 ’24. After this action, Brady Todd C now owns 1,471,298 shares of Aldeyra Therapeutics Inc, valued at $260,238 using the latest closing price.

Machatha Stephen, the Chief Development Officer of Aldeyra Therapeutics Inc, sale 11,537 shares at $3.16 during a trade that took place back on Mar 12 ’24, which means that Machatha Stephen is holding 243,495 shares at $36,503 based on the most recent closing price.

Stock Fundamentals for ALDX

Current profitability levels for the company are sitting at:

  • -109.0 for the present operating margin
  • 0.33 for the gross margin

The net margin for Aldeyra Therapeutics Inc stands at -93.85. The total capital return value is set at -0.34. Equity return is now at value -27.73, with -22.78 for asset returns.

Based on Aldeyra Therapeutics Inc (ALDX), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -1.94. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is -20.66.

Currently, EBITDA for the company is -42.53 million with net debt to EBITDA at 3.42. When we switch over and look at the enterprise to sales, we see a ratio of 208.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.44.

Conclusion

In conclusion, Aldeyra Therapeutics Inc (ALDX) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts